Pharma commercial analytics · Certara
Certara
Biosimulation and drug-development software plus regulatory and market-access consulting for biopharma.
Certara provides software and consulting for quantitative drug development: physiologically based pharmacokinetic (PBPK) modeling, population PK/PD analysis, quantitative systems pharmacology (QSP), and regulatory submission support, alongside a value and market-access practice that produces pricing, reimbursement, and real-world evidence analyses used in commercial and regulatory decisions. Its software, including the Phoenix/WinNonlin and Simcyp product lines, is used by biopharma companies, CROs, and regulatory agencies to simulate how a drug behaves in the body and to support submissions without relying solely on additional real-world trials. Certara's market-access and real-world-evidence consulting arm extends this quantitative base into commercial questions such as pricing strategy and payer evidence, distinguishing it from field-force and CRM-layer analytics vendors like Aktana. It serves biopharma sponsors, CROs, and regulators across roughly 60 countries, spanning both drug-development science and downstream commercialization support.
At a glance
| Vendor | Certara |
|---|---|
| Pricing model | Quote only |
| Free tier | No |
| Deployment | Cloud, Self-hosted |
| Open source | No |
| Best for | Biopharma teams needing quantitative modeling for regulatory submissions plus downstream pricing/market-access analysis. |
Pricing
Software licenses and consulting engagements are quoted directly by Certara; no public price list.
Pricing has not been verified yet — see the vendor's site.
Features
- PBPK modeling (Simcyp)
- Population PK/PD and NCA analysis (Phoenix/WinNonlin)
- Quantitative systems pharmacology (QSP) modeling
- Regulatory submission and writing support
- Pricing, reimbursement, and market-access consulting
- Real-world evidence generation and analysis
- Certara.AI platform for life-sciences AI workflows
Profile last reviewed September 21, 2026